Provided by Tiger Fintech (Singapore) Pte. Ltd.

Ecopetrol SA

8.29
+0.13001.59%
Pre-market: 8.290.00000.00%04:16 EDT
Volume:2.61M
Turnover:21.58M
Market Cap:17.04B
PE:5.09
High:8.45
Open:8.45
Low:8.18
Close:8.16
Loading ...

Biogen, Eisai: EC Asks CHMP to Take Another Look at Leqembi

Dow Jones
·
31 Jan

Ecopetrol S.A. submitted the Report on the Implementation of Best Corporate Practices - "Código País" for FY2024

PR Newswire
·
31 Jan

Bradesco Upgrades Ecopetrol to Outperform From Neutral, $12 Price Target

MT Newswires Live
·
30 Jan

Avnet Reports Second Quarter 2025 Financial Results

Business Wire
·
29 Jan

EC proposes tariffs on fertilizers from Russia and Belarus

TIPRANKS
·
29 Jan

European Equities Close Mixed in Monday Trading; Tesla Sues EC Over China Duties

MT Newswires Live
·
28 Jan

Governance structure for T+1 settlement launches

ETF stream
·
23 Jan

Petrobras Delivers Record-Setting Refinery Output in 2024

Zacks
·
20 Jan

Junshi Biosciences Announces Commercialization Partnership with LEO Pharma for Toripalimab in Europe

GlobeNewswire
·
20 Jan

EC Healthcare Updates Hong Kong Share Registrar Name

TIPRANKS
·
20 Jan

EC World REIT Convenes Key Meeting to Discuss Strategic Directions

TIPRANKS
·
20 Jan

EC Healthcare Shareholders to Vote Feb. 5 on Sale, Purchase Contracts

MT Newswires Live
·
20 Jan

EC Healthcare Announces EGM for Key Acquisition and Disposal Agreements

TIPRANKS
·
20 Jan

ECOPETROL S.A. reports on the decision adopted by the Court of the Southern District of New York on the arbitration ruling issued in favor of Refinería de Cartagena S.A.S.

PR Newswire
·
17 Jan

InflaRx Stock Rises 8% on Conditional EC Nod for COVID-19 Drug

Zacks
·
16 Jan

Ecopetrol announces changes in senior management

PR Newswire
·
16 Jan

Ecopetrol agrees to temporary 50% cut in conversion cost for ADR purchase, sale

TIPRANKS
·
16 Jan

Ecopetrol agrees to a temporary 50% reduction in the conversion cost for the purchase and sale of its ADRs

PR Newswire
·
16 Jan

InflaRx announces EC grants marketing authorization to Gohibic for ARDS

TIPRANKS
·
16 Jan

InflaRx Receives European Commission Approval for GOHIBIC® (vilobelimab) for the Treatment of SARS-CoV-2-Induced Acute Respiratory Distress Syndrome (ARDS)

GlobeNewswire
·
16 Jan